Indo-MIM launches IPO at 45x earnings despite concentration risks
Indo-MIM, the global market leader in metal injection moulding, is going public with a premium valuation that rests on strong profit growth but carries significant geographic and customer concentration risks.
Indo-MIM has filed for an initial public offering, seeking a price-earnings multiple of up to 45 times its fiscal year 2026 earnings. The metal injection moulding specialist is pricing the issue at six times sales as it taps public markets to fund its next phase of expansion.
The company is bringing strong growth metrics to the listing. Between FY24 and FY26, revenue grew at an annual rate of 20.9% to reach ₹4,193 crore, while net profit surged 37.1% annually to ₹533.5 crore. Operating cash flow expanded at a 53.3% annual clip over the two-year period, hitting ₹1,077.2 crore in FY26.
Despite the top-line momentum, the company's profitability profile showed signs of strain in its most recent year. While FY26 revenue and net profit both jumped 25.9% year-on-year, EBITDA growth lagged at 14.8%. Consequently, EBITDA margins contracted to 25.5% from 28% in FY25.
Indo-MIM commands a dominant position in its niche. A Frost & Sullivan report identifies it as the market leader in the metal injection moulding segment. The company operates 15 manufacturing facilities spread across India, the US, the UK and Mexico, supplying finished components to the automotive, defence, medical, consumer and aerospace sectors.
Investors will need to weigh this market leadership against notable operational risks. Nearly 30% of Indo-MIM's revenue comes from its top five customers. Furthermore, the business is heavily exposed to foreign markets, with exports accounting for 77.2% of total revenue. North America alone generates 44% of sales, leaving the company vulnerable to regional trade shifts or economic downturns.
The lack of a direct listed peer in India makes the valuation benchmark difficult for market participants to assess. At a maximum P/E of 45, the IPO prices the manufacturer at a significant premium. Institutional investors will have to determine if the company's specialised capabilities and cash generation justify that multiple given its concentrated revenue base.
